SCHEMBL6347785

SCHEMBL6347785

CCN1C(=O)c2cccc3c(Cl)ccc(c23)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
KDM4E B2RXH2 4/20 1.00
LMNA P02545 2/20 1.00
L3MBTL1 Q9Y468 1/20 0.78
HPGD P15428 2/20 0.69
CYP1B1 Q16678 5/20 0.68
KMT2A Q03164 4/20 0.68
MEN1 O00255 3/20 0.68
USP2 O75604 2/20 0.68
ATM Q13315 1/20 0.68
KEAP1 Q14145 1/20 0.68
NFE2L2 Q16236 1/20 0.68
MAPT P10636 3/20 0.64
CYP1A2 P05177 1/20 0.64
POLB P06746 1/20 0.64
ERCC1 P07992 1/20 0.64
TSHR P16473 1/20 0.64
ALOX12 P18054 1/20 0.64
FEN1 P39748 1/20 0.64
ERCC4 Q92889 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30153490 1.00 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL17726925 0.88 ALDH1A1 (0.78) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL10267893 0.87 ALDH1A1 (0.77) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL6887733 0.85 ALDH1A1 (0.74) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL11932614 0.83 ALDH1A1 (0.70) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL3888669 0.83 ALDH1A1 (0.70) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL11629372 0.83 KDM4E (0.70) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL17407730 0.82 CYP1B1 (0.69) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL16213400 0.81 KDM4E (1.00) ALDH1A1KDM4ELMNAL3MBTL1HPGD
SCHEMBL7735555 0.81 KDM4E (0.68) ALDH1A1KDM4ELMNAL3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023006909-A1 FUNCTIONALISATION OF CARBOXYMETHYLCELLULOSE THE UNIVERSITY OF MANCHESTER (GB) 2023-02-02 WO disclosed
CN-107417616-A Methods and compositions for treating beta-thalassemia and sickle cell disease 中央研究院 2017-12-01 CN disclosed
US-20170290820-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2017-10-12 US disclosed
US-20170290820-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2017-10-12 US disclosed
US-20170290820-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2017-10-12 US disclosed
US-9662324-B2 Methods and compositions for treating β-thalassemia and sickle cell disease ACADEMIA SINICA (TW) 2017-05-30 US disclosed
US-9662324-B2 Methods and compositions for treating β-thalassemia and sickle cell disease ACADEMIA SINICA (TW) 2017-05-30 US disclosed
US-9662324-B2 Methods and compositions for treating β-thalassemia and sickle cell disease ACADEMIA SINICA (TW) 2017-05-30 US disclosed
US-20160106728-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2016-04-21 US disclosed
US-20160106728-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2016-04-21 US disclosed
US-20160106728-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2016-04-21 US disclosed
CN-105492428-A Methods and compositions for treating beta-thalassemia and sickle cell disease ACADEMIA SINICA 2016-04-13 CN disclosed
WO-2014179567-A2 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE ACADEMIA SINICA (TW) 2014-11-06 WO disclosed
EP-1975160-B1 Polymerizable compound, polymer, ink composition, printed articles and inkjet recording method FUJIFILM CORP (JP) 2013-01-16 EP disclosed
US-8173226-B2 Polymerizable compound , polyethylene glycol mono(meth)acrylate, a polystyrene oligomer having a methacryloyl group at one terminal, acrylic macromonomer imides FUJIFILM CORPORATION (JP) 2012-05-08 US disclosed
US-8173226-B2 Polymerizable compound , polyethylene glycol mono(meth)acrylate, a polystyrene oligomer having a methacryloyl group at one terminal, acrylic macromonomer imides FUJIFILM CORPORATION (JP) 2012-05-08 US disclosed
US-20090214797-A1 INKJET INK COMPOSITION, AND INKJET RECORDING METHOD AND PRINTED MATERIAL EMPLOYING SAME FUJIFILM CORPORATION (JP) 2009-08-27 US disclosed
US-20090214797-A1 INKJET INK COMPOSITION, AND INKJET RECORDING METHOD AND PRINTED MATERIAL EMPLOYING SAME FUJIFILM CORPORATION (JP) 2009-08-27 US disclosed
US-20080241416-A1 POLYMERIZABLE COMPOUND, POLYMER, INK COMPOSITION, PRINTED ARTICLES AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed
US-20080241416-A1 POLYMERIZABLE COMPOUND, POLYMER, INK COMPOSITION, PRINTED ARTICLES AND INKJET RECORDING METHOD FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241416-A1 POLYMERIZABLE COMPOUND, POLYMER, INK COMPOSITION, PRINTED ARTICLES AND INKJET RECORDING METHOD CNOT1, CCNT1, SCO2 ALDH1A1 1750/4885KDM4E 930/4885LMNA 3111/4885
US-20170290820-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE HBB, HBZ, HBG1 ALDH1A1 921/4885KDM4E 4391/4885LMNA 120/4885
US-20160106728-A1 METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE HBB, HBZ, HBG1 ALDH1A1 921/4885KDM4E 4391/4885LMNA 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.